Prime Cabinet Secretary Musalia Mudavadi has lauded two Kenyan scientists in the United States for their groundbreaking work in developing a pediatric treatment for sickle cell disease. During his visit to Morgantown, West Virginia, Mudavadi commended Dr. Wycliffe Omwancha and Charles Otieno, co-founders of Yunigen Inc., for their innovation in creating Scedamin—a dissolvable hydroxyurea tablet designed specifically for children aged nine months and older.

Scedamin addresses several challenges associated with administering hydroxyurea to children, such as dosing inaccuracies from breaking open traditional capsules. This formulation is easy to administer, portable, and does not require refrigeration, making it particularly suitable for use in rural and resource-limited settings.

Approximately 70% of the 120 million people worldwide living with sickle cell disease reside in Africa. Data shows that each year, about 240,000 children are … percent receive treatment. Tragically, between … % and 80% of these children die before reaching … .

Mudavadi emphasized the need for continued international collaboration … . He highlighted Kenya’s commitment to addressing the disease through initiatives such as enhancing newborn screening programs and incorporating sickle cell disease into national health policies.

The launch of Scedamin … , underscoring the importance of global partnerships in tackling health challenges. Mudavadi’s visit and endorsement reflect Kenya’s dedication to supporting innovative solutions for sickle cell disease and improving the health outcomes of its citizens.

The development of Scedamin marks a significant step forward in the fight against sickle cell disease, offering hope to thousands of children and families affected by this condition.